This Fund Sold $9 Million of Ligand Stock After an 84% Rally - What Investors Should Know
A high-conviction fund just trimmed one of its biggest winners-here's what long-term investors should make of the move.
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Orchestra BioMed Holdings, Inc. ( Nasdaq: OBIO, "Orchestra BioMed" or the "Company" ) , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the ...
Pelthos Therapeutics Acquires Xepi® ( ozenoxacin ) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
DURHAM, N.C., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Pelthos Therapeutics Inc. ( NYSE American: PTHS ) , a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ( "Pelthos" ) , today announced it has acquired the U.S. commercialization rights ...
Pelthos Therapeutics Acquires Xepi® ( ozenoxacin ) Cream, 1% and Announces $18 Million Private Convertible Notes Financing - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Pelthos Therapeutics ( AMEX:PTHS )
Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™ Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting ...
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch - Pelthos Therapeutics ( AMEX:PTHS )
Pelthos Therapeutics Inc. ( NYSE:PTHS ) on Friday acquired the U.S. commercialization rights to Xepi ( ozenoxacin ) Cream, 1%, from Biofrontera Inc. ( NASDAQ:BFRI ) and Ferrer Internacional S.A.
Ligand ( LGND ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, Nov. 6, 2025, at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Ligand to Host Investor Day on December 9, 2025 - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND ) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:30 a.m. to 12:00 p.m. Eastern Time at The Harvard Club.
Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors
Industry leader brings 40 years of executive and board experience across the global medical technology sector ...
Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors - Elutia ( NASDAQ:ELUT )
Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 ( GLOBE NEWSWIRE ) -- Elutia Inc. ( NASDAQ:ELUT ) ( "Elutia" or the "Company" ) , a pioneer in drug-eluting biomatrix technologies, announced the ...
Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum - Pelthos Therapeutics ( AMEX:PTHS )
The Moms Against Molluscum movement aims to empower families impacted by molluscum to share their personal stories and encourage others to join the conversation Molluscum is a highly contagious skin infection affecting 16.7 million Americans, mainly children
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
JUPITER, Fla., Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) today announced that its partner SQ Innovation Inc. has received approval from the U.S.
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million - Boston Scientific ( NYSE:BSX ) , Elutia ( NASDAQ:ELUT )
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market -
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform ...
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide - X4 Pharmaceuticals ( NASDAQ:XFOR ) , Altimmune ( NASDAQ:ALT )
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH ...
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292
Arecor Therapeutics announces Co-development Agreement for AT278 with Sequel Med Tech and Sale of Royalty and Technology Access Fees for up to ...
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device ( CIED ) pocket management ...
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation - Elutia ( NASDAQ:ELUT )
- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device ( CIED ) pocket management - GAITHERSBURG, Md., Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Elutia Inc.
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
DURHAM, N.C., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Pelthos Therapeutics Inc. ( NYSE American: PTHS ) , a biopharmaceutical company ( "Pelthos" or the "Company" ) committed to commercializing innovative therapeutic products for high unmet patient needs, today reported financial results for legacy ...
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- Orchestra BioMed Holdings, Inc. ( Nasdaq: OBIO, "Orchestra BioMed" or the "Company" ) , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the ...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to persons ...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to ...
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due ...
Ligand ( LGND ) Q2 Revenue Jumps 15%
Ligand Pharmaceuticals ( NASDAQ:LGND ) , a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7, 2025. The company exceeded analyst estimates with non-GAAP EPS of $1.60 ( consensus: $1.42 ) and reported revenue ...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million ( previously $180 million - $200 million ) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 ( previously $6.00 - $6.25 )
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Medtronic ( NYSE:MDT )
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
Ligand to Report Second Quarter 2025 Financial Results on August ...
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., July 24, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m.
Why Is Pelthos Therapeutics Stock Trading Higher Thursday - Pelthos Therapeutics ( AMEX:PTHS )
Zelsuvmi cleared all molluscum lesions in 33% of patients vs. 19.7% on placebo by week 12 in 891-patient trial. Zelsuvmi is FDA-approved for at-home use in adults and children as young as one year old. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the ...
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
Ligand Partner Pelthos Therapeutics Launches ...
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - First Majestic Silver ( NYSE:AG ) , AES ( NYSE:AES )
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Verona Pharma plc VRNA rose sharply during Wednesday's session after Merck announced it will acquire the company in a $10 billion deal.
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Channel Therapeutics ( AMEX:CHRO )
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - Ligand Pharmaceuticals ( NASDAQ:LGND )
Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI
Ligand to Participate in May Investor Conferences - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., May 01, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference ( Virtual ) .
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 01, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) today announced that its senior management team will participate in the following upcoming investor conferences: • H.C. Wainwright Royalty Company Conference ( Virtual ) .
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Adagio Medical Holdings ( NASDAQ:ADGM ) , Channel Therapeutics ( AMEX:CHRO )
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 450 points on Thursday. The Dow traded down 1.20% to 39,191.93 while the NASDAQ fell 0.09% to 16,293.14. However, the S&P 500 gained 0.30% to 5,291.42. Energy shares surged by 2.5% on Thursday.
Dow Falls Over 1%; US Initial Jobless Claims Decline - Adagio Medical Holdings ( NASDAQ:ADGM ) , Channel Therapeutics ( AMEX:CHRO )
U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded down 1.22% to 39,187.35 while the NASDAQ gained 0.28% to 16,352.96. The S&P 500 also rose, gaining, 0.11% to 5,281.74.
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Channel Therapeutics ( AMEX:CHRO )
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Channel Therapeutics ( AMEX:CHRO )
Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin infection affecting 16.7 million in the U.S. Feel unsure about the market's next move?
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy - Ligand Pharmaceuticals ( NASDAQ:LGND )
Stifel starts Ligand coverage with Buy rating, $43 target; cites strong royalty-financing model and biotech partnerships. Ligand posts 20%+ revenue and 35%+ EPS growth since 2022 restructure, driven by scalable platforms and lean operations. Pelosi's latest AI pick skyrocketed 169% in just one ...
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Ligand Pharmaceuticals ( NASDAQ:LGND ) , MannKind ( NASDAQ:MNKD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B of A Securities analyst Joshua Dennerlein initiated coverage on MSCI Inc.
Ligandrol ( LGD-4033 ) SARMs: Ligandrol Benefits, Ligandrol Results & Buy Ligandrol Pills Alternatives Ligan 4033 By CrazyBulk
NEW YORK, April 03, 2025 ( GLOBE NEWSWIRE ) -- "We've got several pro bodybuilding athletes ready and waiting to get to know you in our free private CrazyBulk community. And you'll receive an invite to it the minute you purchase any CrazyBulk product.
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare ...
Ligand to Participate in March Investor Conferences - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., March 03, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences:
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol "PVLA" as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases ...
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol "PVLA" as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Lifecore Biomedical ( NASDAQ:LFCR )
WAYNE, Pa., Oct. 17, 2024 ( GLOBE NEWSWIRE ) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, ...
